Global Kidney Cancer Diagnostics And Therapeutics Market Forecast 2029: Size, Share, and Competitive Landscape
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Kidney Cancer Diagnostics And Therapeutics Market In The Coming Years?
In recent times, the market size for kidney cancer diagnostics and therapeutics has witnessed robust growth. The market is expected to expand from $4.1 billion in 2024 to $4.31 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historical period is linked to factors such as advancements in molecular biology research, clinical trials, and drug development, as well as innovations in surgery, discoveries in genetics, and improved accessibility to healthcare.
The diagnostics and therapeutics market for kidney cancer is anticipated to witness robust expansion in the forthcoming years, escalating to $5.65 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the prediction period can be ascribed to factors such as biomarker research, advancements in genomic sequencing, the rise of telemedicine and remote consultations, improvements in precision medicine, and the evolution of rapid diagnostic technologies. During the projection period, the principal trends to expect include the integration of palliative care, the focus on long-term survivorship care, intervention through nutrition and lifestyle, an extended incorporation of radiomics, and the widespread utilization of liquid biopsies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Kidney Cancer Diagnostics And Therapeutics Market?
The rise in kidney cancer cases is anticipated to fuel the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer is a disease that begins when the cells in one or both kidneys develop abnormalities and grow uncontrollably, creating a mass known as a renal cortical tumor. Diagnostics and therapeutics are essential for managing and treating kidney cancer, providing a range of benefits like early detection, precise diagnosis, selecting the most appropriate treatment, tailoring medicine to the individual, and monitoring the treatment’s effectiveness. For instance, the American Society of Clinical Oncology (ASCO), a non-profit organization dedicated to cancer care in the US, estimated in March 2023 that 81,800 people in the US (52,360 men and 29,440 women) will be diagnosed with kidney cancer in 2023. In 2020, kidney cancer affected 431,288 individuals worldwide. Consequently, the escalating incidence of kidney cancer is presumed to stimulate the expansion of the kidney cancer diagnostics and therapeutics market.
Which Sub-Segments Are Driving Growth Within The Kidney Cancer Diagnostics And Therapeutics Market?
The kidney cancer diagnostics and therapeuticsmarket covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC; Papillary RCC; Chromophobe RCC; Urothelial Carcinoma And Transitional Cell Carcinoma; Other Cancer Types
2) By Component: Drugs; Diagnostics
3) By Diagnostics: Biopsy; CT Scan; Nephro-Ureteroscopy; Intravenous Pyelogram; Ultrasound
4) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy
5) By End-Users: Hospitals; Pharmaceutical Labs; Genomics Laboratories
Subsegments:
1) By Clear Cell RCC: Stage I; Stage II; Stage III; Stage IV
2) By Papillary RCC: Type 1; Type 2
3) By Chromophobe RCC: Localized; Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive; Muscle invasive; Metastatic
5) By Other Cancer Types: Collecting Duct Carcinoma; Renal Medullary Carcinoma; Other rare types
What Current And Upcoming Trends Are Shaping The Kidney Cancer Diagnostics And Therapeutics Market?
Top firms in the kidney cancer diagnostics and therapeutics market are making efforts to develop cutting-edge renal cell carcinoma (RCC) solutions to enhance patient experiences while providing custom-made treatment methods for those with this challenging health condition. Ongoing research into renal cell carcinoma (RCC) is crucial in the kidney cancer diagnostics and therapeutics industry as it leads to the invention of innovative diagnostic procedures and specialized treatments, which enhance early detection and personalized care for patients. As an illustration, in December 2023, Merck, an American pharmaceutical firm, introduced welireg (belzutifan), the premier hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for adult patients dealing with advanced renal cell carcinoma (RCC) following previous treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This groundbreaking therapeutic category demonstrates significant advantages, including enhanced progression-free survival and better response rates than everolimus. The endorsement of WELIREG denotes a vital accomplishment in the kidney cancer diagnostics and therapeutics market, presenting renewed hope for patients battling with the progressive disease.
Which Players Are Shaping The Competitive Landscape Of The Kidney Cancer Diagnostics And Therapeutics Market?
Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited
Access The Complete Report Here:
How Do Regional Dynamics Influence The Kidney Cancer Diagnostics And Therapeutics Market Performance?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=11937&type=smp
Browse Through More Reports Similar to the Global Kidney Cancer Diagnostics And Therapeutics Market 2025, By The Business Research Company
Pain Management Devices And Therapies Global Market Report 2025
Metabolomics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
Isothermal Nucleic Acid Amplification Technology Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
